These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1521204)

  • 1. Phases in a drug's use.
    Duffin J
    CMAJ; 1992 Sep; 147(5):588. PubMed ID: 1521204
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide induction of bone marrow transplantation tolerance.
    Vogelsang GB; Hess AD; Gordon G; Brundrette R; Santos GW
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2658-61. PubMed ID: 3547944
    [No Abstract]   [Full Text] [Related]  

  • 3. Thalidomide for treatment of graft-versus-host disease.
    Vogelsang GB; Hess AD; Santos GW
    Bone Marrow Transplant; 1988 Sep; 3(5):393-8. PubMed ID: 3056547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation.
    Cole CH; Rogers PC; Pritchard S; Phillips G; Chan KW
    Bone Marrow Transplant; 1994 Dec; 14(6):937-42. PubMed ID: 7711671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of thalidomide for CGVHD defended.
    Altomonte V
    Oncol Nurs Forum; 1993 Apr; 20(3):428. PubMed ID: 8497414
    [No Abstract]   [Full Text] [Related]  

  • 6. [Thalidomide 1989].
    Codina C
    Med Clin (Barc); 1989 Apr; 92(15):571-2. PubMed ID: 2666770
    [No Abstract]   [Full Text] [Related]  

  • 7. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.
    Chao NJ; Parker PM; Niland JC; Wong RM; Dagis A; Long GD; Nademanee AP; Negrin RS; Snyder DS; Hu WW; Gould KA; Tierney DK; Zwingenberger K; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):86-92. PubMed ID: 9118303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
    Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
    Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model.
    Vogelsang GB; Wells MC; Santos GW; Chen TL; Hess AD
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):226-8. PubMed ID: 3284069
    [No Abstract]   [Full Text] [Related]  

  • 10. Failure of thalidomide to control bronchiolitis obliterans post bone marrow transplant.
    Heaton DC
    Bone Marrow Transplant; 1989 Sep; 4(5):598. PubMed ID: 2790340
    [No Abstract]   [Full Text] [Related]  

  • 11. Thalidomide as therapy for intestinal chronic GVHD.
    Lopez J; Ulibarrena C; Garcia-Laraña J; Odriozola J; Pérez de Oteyza J; Sastre JL; Navarro JL
    Bone Marrow Transplant; 1993 Mar; 11(3):251-2. PubMed ID: 8467293
    [No Abstract]   [Full Text] [Related]  

  • 12. Thalidomide responsive chronic pulmonary GVHD.
    Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GA
    Bone Marrow Transplant; 1996 Feb; 17(2):291-3. PubMed ID: 8640183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide back in good graces--seems to help GVHD patients.
    Oncology (Williston Park); 1988 Sep; 2(9):29. PubMed ID: 3275064
    [No Abstract]   [Full Text] [Related]  

  • 14. Quest to improve marrow transplant success yields new approaches to graft-vs-host disease.
    Kirn TF
    JAMA; 1987 Sep; 258(11):1438-9. PubMed ID: 3306001
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
    Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
    Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prevention of graft-vs-host disease following allogeneic bone marrow transplantation].
    de Witte T; Janssen J; de Pauw B; Holdrinet R; Wessels J; Haanen C
    Ned Tijdschr Geneeskd; 1986 Jul; 130(28):1290-1. PubMed ID: 3528870
    [No Abstract]   [Full Text] [Related]  

  • 17. Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation.
    Champlin R
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):46-52. PubMed ID: 1509294
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
    Truog AW; Wozniak SP
    Oncol Nurs Forum; 1990; 17(1):39-44. PubMed ID: 2405360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thalidomide for graft-versus-host disease after bone marrow transplantation.
    Saurat JH; Camenzind M; Helg C; Chapuis B
    Lancet; 1988 Feb; 1(8581):359. PubMed ID: 2893167
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.